Global Blood Therapeutics, Inc. (NASDAQ:GBT) – Analysts at SunTrust Banks boosted their FY2018 earnings estimates for Global Blood Therapeutics in a report issued on Monday. SunTrust Banks analyst Y. Suneja now expects that the company will earn ($3.30) per share for the year, up from their prior forecast of ($4.10). SunTrust Banks has a “Buy” rating and a $67.00 price target on the stock. SunTrust Banks also issued estimates for Global Blood Therapeutics’ FY2019 earnings at ($3.45) EPS, FY2020 earnings at ($3.55) EPS and FY2021 earnings at ($4.40) EPS.

Global Blood Therapeutics (NASDAQ:GBT) last released its earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.04). During the same quarter in the previous year, the business earned ($0.58) earnings per share.

Other analysts have also issued research reports about the company. Needham & Company LLC started coverage on Global Blood Therapeutics in a report on Wednesday, September 20th. They issued a “buy” rating and a $51.00 target price on the stock. Oppenheimer set a $53.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research raised Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a report on Tuesday, October 10th. J P Morgan Chase & Co reissued a “buy” rating on shares of Global Blood Therapeutics in a report on Monday, October 23rd. Finally, BidaskClub raised Global Blood Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $56.38.

Global Blood Therapeutics (NASDAQ:GBT) traded up $0.25 on Wednesday, reaching $40.00. The company’s stock had a trading volume of 579,600 shares, compared to its average volume of 989,377. Global Blood Therapeutics has a 12-month low of $13.35 and a 12-month high of $43.95.

In related news, insider Jung Choi sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $32.65, for a total transaction of $97,950.00. Following the completion of the transaction, the insider now owns 138,455 shares in the company, valued at approximately $4,520,555.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Peter Radovich sold 12,500 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $35.00, for a total value of $437,500.00. Following the transaction, the vice president now owns 2,684 shares of the company’s stock, valued at approximately $93,940. The disclosure for this sale can be found here. Insiders have sold a total of 88,500 shares of company stock worth $3,003,350 in the last three months. 5.30% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the stock. Sphera Funds Management LTD. bought a new position in shares of Global Blood Therapeutics during the 2nd quarter worth approximately $4,103,000. Emory University bought a new position in shares of Global Blood Therapeutics during the 2nd quarter worth approximately $1,442,000. Marcus Capital LLC lifted its position in shares of Global Blood Therapeutics by 25.7% during the 2nd quarter. Marcus Capital LLC now owns 65,350 shares of the company’s stock worth $1,787,000 after buying an additional 13,350 shares during the period. Citigroup Inc. lifted its position in shares of Global Blood Therapeutics by 1,544.9% during the 2nd quarter. Citigroup Inc. now owns 87,819 shares of the company’s stock worth $2,402,000 after buying an additional 82,480 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in shares of Global Blood Therapeutics by 211.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 317,571 shares of the company’s stock worth $8,686,000 after buying an additional 215,690 shares during the period. Institutional investors and hedge funds own 90.48% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Global Blood Therapeutics, Inc. (GBT) Forecasted to Post FY2018 Earnings of ($3.30) Per Share” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/06/global-blood-therapeutics-inc-gbt-forecasted-to-post-fy2018-earnings-of-3-30-per-share.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.